Celecoxib Combined with Thalidomide in the Treatment of Refractory Neoplastic Fever in Advanced Cholangiocarcinoma: A Case Report

A B S T R A C T

Neoplastic fever, a common symptom of tumors, can be mainly controlled by nonsteroidal anti-inflammatories (NSAIDs) and corticosteroids. However, there is no standard treatment guideline for refractory neoplastic fever, which cannot be controlled by the medicines mentioned above. This report presents a case of advanced cholangiocarcinoma with persistent fever lasting 3 weeks. After ineffective treatment with various antibiotics, ibuprofen, and corticosteroids, the body temperature returned to normal after a 48-hour treatment with celecoxib + thalidomide. Finally, the overall survival (OS) of the patient reached 8 months with radiotherapy and chemotherapy.

Keywords

Celecoxib, thalidomide, neoplastic fever, cholangiocarcinoma

Get access to the full version of this article.

Article Info

Article Type

Publication history

Copyright

Author Info

Qiu-yuan Liang Kaijian Lei Shan-Bing Wang Yue Ren Yan Xu

Corresponding Author

Figures & Tables

Get access to the full version of this article.

References

1. Browder AA, Huff JW, Petersdorf RG (1961) The significance of fever in neoplastic disease. Ann Intern Med 55: 932-942. [Crossref]
2. Toussaint E, Bahel Ball E, Vekemans M, Georgala A, Al Hakak L et al. (2006) Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer 14: 763-769. [Crossref]
3. Zell JA, Chang JC (2005) Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer 13: 870-877. [Crossref]
4. Johnson M (1996) Neoplastic Fever. Palliat Med 10: 217-224. [Crossref]
5. Chang JC (1988) Antipyretic effect of naproxen and corticosteroidss on neoplastic fever. J Pain Symptom Manage 3: 141-144. [Crossref]
6. Tsavaris N, Zinelis A, Karabelis A, Beldecos D, Bacojanis C et al. (1990) A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever. J Intern Med 228: 451-455. [Crossref]
7. Rolston KVI (2005) Neoplastic fever: all who shiver are not infected. Support Care Cancer 13: 863-864. [Crossref]
8. Farley DR, Weaver AL, Nagorney DM (1995) “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 70: 425-429. [Crossref]
9. Gong ZJ, Cheng JW, Gao PT, Huang A, Sun YF et al. (2019) Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. Oncologist 24: 997-1007. [Crossref]
10. Rizvi S, Gores GJ (2013) Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. Gastroenterology 145: 1215-1229. [Crossref]
11. Wójcik M, Ramadori P, Blaschke M, Sultan S, Khan S et al. (2012) Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma. Histochem Cell Biol 137: 217-233. [Crossref]
12. Furey SA, Waksman JA, Dash BH (1992) Nonprescription ibuprofen: side effect profile. Pharmacotherapy 12: 403-407. [Crossref]
13. Lipsky PE, Isakson PC (1997) Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol Suppl 49: 9-14. [Crossref]
14. Chaulet C, Croix C, Alagille D, Normand S, Delwail A et al. (2011) Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors. Bioorg Med Chem Lett 21: 1019-1022. [Crossref]
15. Wu GS, Zou SQ, Liu ZR, Tang ZH, Wang JH et al. (2003) Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 9: 1302-1306. [Crossref]
16. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T et al. (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418-425. [Crossref]
17. Liu KH, Liao LM, Ro LS, Wu YL, Yeh TS (2008) Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats. Surgery 143: 375-383. [Crossref]
18. Hada M, Horiuchi T, Shinji H (2006) A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine. Gan to Kagaku Ryoho 33: 259-261. [Crossref]
19. Wang XS, Woodruff JF (2015) Cancer-related and treatment-related fatigue. Gynecol Oncol 136: 446-452. [Crossref]
20. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699-703. [Crossref]